Jun Terashima

Dr. Jun Terashima


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2015 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
WHWataru Habano
Wataru Habano
KKKohei Kawamura
Kohei Kawamura
NINatsuki Iizuka
Natsuki Iizuka
JTJun Terashima
Jun Terashima
TSTamotsu Sugai
Tamotsu Sugai
Shogo OzawaShogo Ozawa
Shogo Ozawa
Drug metabolizing enzymes (DMEs) exhibit dramatic inter- and intra-individual variability in expression and activity. However, the mechanisms determining this variability have not been fully elucidated. The aim of this study was to evaluate the biological significance of DNA methylation in the regulation of DME genes by genome-wide integrative analysis. DNA methylation and mRNA expression profiles of human tissues and hepatoma cells were examined by microarrays. The data were combined with GEO datasets of liver tissues, and integrative analysis was performed on selected DME genes. Detailed DNA methylation statuses at individual CpG sites were evaluated by DNA methylation mapping. From analysis of 20 liver tissues, highly variable DNA methylation was observed in 37 DME genes, 7 of which showed significant inverse correlations between DNA methylation and mRNA expression. In hepatoma cells, treatment with a demethylating agent resulted in upregulation of 5 DME genes, which could be explained by DNA methylation status. Interestingly, some DMEs were suggested to act as tumor-suppressor or housekeeper based on their unique DNA methylation features. Moreover, tissue-specific and age-dependent expression of UDP-glucuronosyltransferase 1A splicing variants was associated with DNA methylation status of individual first exons. Some DME genes were regulated by DNA methylation, potentially resulting in inter- and intra-individual differences in drug metabolism. Analysis of DNA methylation landscape facilitated elucidation of the role of DNA methylation in the regulation of DME genes, such as mediator of inter-individual variability, guide for correct alternative splicing, and potential tumor-suppressor or housekeeper.

22 February 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
WHWataru Habano
Wataru Habano
TGToshie Gamo
Toshie Gamo
JTJun Terashima
Jun Terashima
TSTamotsu Sugai
Tamotsu Sugai
KOKoki Otsuka
Koki Otsuka
Shogo OzawaShogo Ozawa
Shogo Ozawa
Pregnane X receptor (PXR) is a key transcription factor that regulates drug metabolizing enzymes such as cytochrome P450 (CYP) 3A4, and plays important roles in intestinal first-pass metabolism. Although there is a large inter-individual heterogeneity with intestinal CYP3A4 expression and activity, the mechanism driving these differences is not sufficiently explained by genetic variability of PXR or CYP3A4. We examined whether epigenetic mechanisms are involved in the regulation of PXR/CYP3A4 pathways in colon cancer cells. mRNA levels of PXR, CYP3A4 and vitamin D receptor (VDR) were evaluated by quantitative real-time PCR on 6 colon cancer cell lines (Caco-2, HT29, HCT116, SW48, LS180, and LoVo). DNA methylation status was also examined by bisulfite sequencing of the 6 cell lines and 18 colorectal cancer tissue samples. DNA methylation was reversed by the treatment of these cell lines with 5-aza-2'-deoxycytidine (5-aza-dC). The 6 colon cancer cell lines were classified into two groups (high or low expression cells) based on the basal level of PXR/CYP3A4 mRNA. DNA methylation of the CpG-rich sequence of the PXR promoter was more densely detected in the low expression cells (Caco-2, HT29, HCT116, and SW48) than in the high expression cells (LS180 and LoVo). This methylation was reversed by treatment with 5-aza-dC, in association with re-expression of PXR and CYP3A4 mRNA, but not VDR mRNA. Therefore, PXR transcription was silenced by promoter methylation in the low expression cells, which most likely led to downregulation of CYP3A4 transactivation. Moreover, a lower level of PXR promoter methylation was observed in colorectal cancer tissues compared with adjacent normal mucosa, suggesting upregulation of the PXR/CYP3A4 mRNAs during carcinogenesis. PXR promoter methylation is involved in the regulation of intestinal PXR and CYP3A4 mRNA expression and might be associated with the inter-individual variability of the drug responses of colon cancer cells.

1 January 2013 in BMC Molecular Biology
Verified
Journal Article
Open access
PDF file
JTJun Terashima
Jun Terashima
CTChie Tachikawa
Chie Tachikawa
KKKenzo Kudo
Kenzo Kudo
WHWataru Habano
Wataru Habano
Shogo OzawaShogo Ozawa
Shogo Ozawa
Aryl hydrocarbon receptor (AhR) not only regulates drug-metabolizing enzyme expression but also regulates cancer malignancy. The steps to the development of malignancy include angiogenesis that is induced by tumor microenvironments, hypoxia, and nutrient deprivation. Vascular endothelial growth factor (VEGF) plays a central role in the angiogenesis of cancer cells, and it is induced by activating transcription factor 4 (ATF4).

1 December 2015 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
JTJun Terashima
Jun Terashima
SGShinpei Goto
Shinpei Goto
HHHiroki Hattori
Hiroki Hattori
SHSawaka Hoshi
Sawaka Hoshi
MUMidori Ushirokawa
Midori Ushirokawa
SOShogo Ozawa
Shogo Ozawa

1 January 2021 in Cancer Drug Resistance
Verified
Journal Article
Open access
PDF file
SOShogo Ozawa
Shogo Ozawa
TMToshitaka Miura
Toshitaka Miura
JTJun Terashima
Jun Terashima
WHWataru Habano
Wataru Habano
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.

30 August 2016 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
JTJun Terashima
Jun Terashima
SSSatoko Sampei
Satoko Sampei
MIMei Iidzuka
Mei Iidzuka
AOAyumi Ohsakama
Ayumi Ohsakama
CTChie Tachikawa
Chie Tachikawa
SOShogo Ozawa
Shogo Ozawa